** Drug developer Dermata Therapeutics' DRMA.O shares rise 8.2% to $1.46 premarket
** Company says its experimental drug xyngari meet primary main goal to treat moderate-to-severe acne in a late-stage study
** Main goals of the late-stage study were to measure the average change in both inflammatory and non-inflammatory skin blemishes and to assess the treatment response using a common scale called Investigator Global Assessment $(IGA)$
** Company says xyngari showed "highly statistically significant and clinically meaningful improvement" in acne compared to placebo after 12 weeks of once-weekly treatment
** Company says it is set to launch the drug in H2 2025
** As of last close, Dermata's shares down ~78% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。